Skip to main contentAI and Advanced
/
ORCHPHARMA · NSEMarket ticker unavailable · configure an authorised index feed
OR
NSE · Equity shares · Biotechnology & Drugs-23.30 · -2.36%
Orchid Pharma ORCHPHARMA
NSE:INR 963.7
BSE:INR 998.7
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for ORCHPHARMA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 987
Day rangeINR 950.2 — INR 992.75
52-week rangeINR 480 — INR 1,133
Volume54,987
Market cap5,041.89
P/E122.18
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)811.33
Net Income (INR Cr)20.55
Rev Growth (5 Year %)12.51
P/E Ratio122.18
Book Value239.38
EPS4.89
Price/BV4.03Computed
Research path: Interpret Orchid Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ORCHPHARMAOrchid Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,910.91 | 1,687.91 | 1,553.87 |
| Cash Equivalents | 83.21 | 179.54 | 266.52 |
| Other Liabilities Total | 11.7 | 3.39 | 3.63 |
| Long Term Debt | 327.73 | 131.64 | 120.43 |
| Common Stock Total | 50.72 | 50.72 | 50.72 |
| Other Current Assets Total | 76.96 | 53.86 | 58.26 |
| Total Assets | 1,910.91 | 1,687.91 | 1,553.87 |
| Current Portof LT Debt/Capital Leases | 30.14 | 0.33 | 0.33 |
| Total Equity | 1,287.79 | 1,267.29 | 1,169.47 |
| Long Term Investments | 56.27 | 53.94 | 51.79 |
| Retained Earnings(Accumulated Deficit) | 1,237.07 | 1,216.57 | 1,118.75 |
| Total Common Shares Outstanding | 5.07 | 5.07 | 5.07 |
| Tangible Book Valueper Share Common Eq | 239.38 | 246.51 | 227.64 |
| Total Liabilities | 623.13 | 420.63 | 384.41 |
| Total Debt | 362.59 | 174.61 | 135.18 |
| Short Term Investments | 0.86 | 3.04 | 4.5 |
| Cashand Short Term Investments | 84.07 | 182.68 | 271.07 |
| Total Receivables Net | 266.45 | 244.51 | 197.19 |
| Accounts Receivable-Trade Net | 263.87 | 241.83 | 195.55 |
| Property/Plant/Equipment Total-Net | 958.67 | 696.41 | 635.99 |
| Total Current Liabilities | 278.97 | 285.57 | 259.97 |
| Total Inventory | 256.41 | 326.37 | 264.23 |
| Accounts Payable | 229.9 | 222.09 | 229.58 |
| Other Currentliabilities Total | 18.93 | 20.54 | 16.02 |
| Total Long Term Debt | 332.45 | 131.67 | 120.8 |
| Intangibles Net | 73.68 | 17.01 | 14.92 |
| Other Long Term Assets Total | 89.68 | 61.83 | 9.13 |
| Note Receivable-Long Term | 48.71 | 51.3 | 51.3 |
| Total Current Assets | 683.9 | 807.42 | 790.75 |
| Capital Lease Obligations | 4.72 | 0.04 | 0.37 |
| Accumulated Depreciation Total | Not available | -703.44 | -669.2 |
| Cash | Not available | 0.1 | 0.04 |
| Property/Plant/Equipment Total-Gross | Not available | 1,335.36 | 1,288.79 |
| Notes Payable/Short Term Debt | Not available | 42.6 | 14.05 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-4.34
Margins
Operating Margin 12m-0.11
Operating Margin 5y Avg5.13
Net Profit Margin 12m2.59
Net Profit Margin 5y5.57
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio6.21
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk46.36
Analyst consensus
ConsensusStrong Buy
Consensus score1.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count0
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 69.84%
- FII
- 0.80%
- MF
- 19.93%
- Other
- 9.43%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
The world needs new antibiotics. Can India deliver them?Market news · 8 Sept 2025, 5:30 pm
Big Pharma is vacating infectious diseases research to chase more lucrative segments like oncology and diabetes. This has left behind a gaping void. A set of Indian companies are diving in—Wockhardt, Orchid Pharma and Bugworks. A successful antibiotic drug can change their fortunes.
Stocks to watch: Vodafone Idea, IRCTC, JSW Steel, HUDCO, Orchid Pharma, Power Grid CorpMarket news · 13 Aug 2024, 8:42 am
Here are a few stocks likely to be in focus on Tuesday, August 13:
Breakout stocks to buy today: From Trent to Orchid Pharma, Sumeet Bagadia recommends these fiveMarket news · 12 Aug 2024, 10:19 am
Bagadia, executive director at Choice Broking, said some stocks that saw fresh breakouts last Friday were still looking positive on the technical chart and recommended them for intraday trading.
Orchid Pharma's most important medical advance in 32 yearsMarket news · 21 Jun 2024, 2:01 pm
Orchid Pharma recently made headlines for securing US FDA approval for a new drug
Orchid Pharma: Investec initiates coverage with 'buy', sees 23% upside – 5 key reasonsMarket news · 11 Dec 2023, 5:40 pm
Despite an over 86 percent gain in the stock in 2023 YTD, domestic brokerage house Investec sees pharma firm Orchid Pharma (ORCD) rising another 23 percent in the next 12 months. The brokerage has initiated coverage on the stock with a ‘buy’ call and a target price of ₹ 800.
Orchid Pharma shares hit 52-week high, rise 5% on launching QIP to raise fundsMarket news · 23 Jun 2023, 11:33 am
Stock market today: Orchid Pharma's share price hits new 52-week high as the drugmaker launches Qualified Institutional Placement issuance to raise capital.
Corporate actions
Events
- board MeetingsAllotment of Equity Shares
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- annual General MeetingCOM
- board MeetingsAudited Results
Rusaka Markets Community
Discussion and sentiment for Orchid Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ORCHPHARMA
- BSE Code
- 524372
Questions
Stock FAQ
What is the symbol and ISIN of Orchid Pharma?
Orchid Pharma has the symbol ORCHPHARMA and ISIN - INE191A01027.
What is the current price of Orchid Pharma?
Orchid Pharma is currently trading at INR 963.70.
What are the year high and year low of Orchid Pharma?
Orchid Pharma has a year high of INR 1,133.00 and a year low of INR 480.00.
What is the market capitalization of Orchid Pharma?
Orchid Pharma has a market capitalization of INR 5,041.89 crore.
What is the P/E ratio of Orchid Pharma?
Orchid Pharma has a P/E ratio of 122.18.
What is the dividend yield of Orchid Pharma?
Orchid Pharma has a dividend yield of 0.00%.
How is the financial performance of Orchid Pharma based on revenue, net income, and EPS?
Orchid Pharma has revenue of INR 811.33 crore, net income of INR 20.55 crore, and EPS of INR 5.25.
What is the book value of Orchid Pharma?
Orchid Pharma has a book value of INR 239.38.
What is the debt-to-equity ratio of Orchid Pharma?
Orchid Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Orchid Pharma?
Orchid Pharma has a price-to-book ratio of 4.03 and a price-to-sales ratio of 6.21.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.